

Key Indices Update

Indices	Close	Change (%)
Nifty	25,062.10	1.607
Sensex	82,530.74	1.487
Midcap	56,530.85	0.707
Smallcap	17,239.95	0.547

Trend Strength Indicator


Nifty 50 Stocks above	NSE Advance /
200 EMA	Decline
36	1980 <mark>/890</mark>

Key Data

Data	Current	Previous
Dow Jones	42,315.5	41,892.5
U.S. Dollar Index	100.68	100.86
Brent Crude (USD/BBL)	64.63	64.84
US 10Y Bond Yield (%)	4.43	4.54
India 10Y Bond Yield (%)	6.29	6.31

Sectoral Data

Sector	Close	Change (%)
BANKNIFTY	55335.90	0.987
NIFTYAUTO	23770.90	1.777
NIFTYENERG	35330.50	0.837
NIFTYFINSR	28365.40	1.287
NIFTYFMCG	56643.95	0.527
NIFTYIT	38243.15	1.037
NIFTYMEDIA	1661.65	1.507
NIFTYMETAL	9197.05	1.607
NIFTYPHARM	21644.80	0.767
NIFTYREALT	897.50	1.877



Market Radiance

Read: Repeat

Top News

- Alembic Pharmaceuticals announced the appointment of Mr. Jigr Shah as Head - Business Finance, effective May 15, 2025. Mr. Shah brings over 20 years of exp. in business finance, with prior roles at Dr. Reddy's Laboratories.
- + Page Industries announced the declaration of a 4th Interim Dividend of ₹200 per equity share for FY24-25. The record date is May 21, 2025, and the payment date is on or before June 13, 2025.

Technical

Refer Page 03-04


- + Nifty regained momentum after a marginal dip, ending the day with gains of nearly one and a half percent.
- + Following a flat start, the Nifty witnessed sharp fluctuations in the first half; however, a decisive surge in heavyweight stocks across sectors drove strong momentum as the session progressed.
- + All major sectors contributed to the rally, with realty, auto, and metals emerging as the top gainers.
- + A decisive breakout above the 25,200 level could potentially take the index towards the 25,400+ zone.
- + We continue to advocate a "buy on dips" strategy, with a strong emphasis on selective stock picking, especially in light of overbought conditions in certain segments.
- + Stock of the day SBIN



Market Radiance

Fundamental

Top News







Technical

Resumed trend after pause. Focus on stock selection.

NIFTY	\$1	S2	RI	R2
25062.10 7 395.20 (1.60%)	24900	24750	25200	25400

Technical Chart : Daily



- Nifty regained momentum after a marginal dip, ending the day with gains of nearly one and a half percent.
- Following a flat start, the Nifty witnessed sharp fluctuations in the first half; however, a decisive surge in heavyweight stocks across sectors drove strong momentum as the session progressed.
- + All major sectors contributed to the rally, with realty, auto, and metals emerging as the top gainers.
- + A decisive breakout above the 25,200 level could potentially take the index towards the 25,400+ zone.

BANKNIFTY	S1	S2	RI	R2	
55355.60 🛪 554.30 (1.01%)	54900	54500	55700	56100	



- The banking index staged a rebound after a two-day breather and closed with one percent gain.
- The heavyweights like Icicibank, Hdcbank, Axisbank performed well, outshining other banking majors reaffirms our positive outlook.
- + A decisive breach of the 55700-56100 zone, could unlock further upside potential.
- + On the downside, 54400-54200 range will act as support zone.
- Traders are advised to continue with 'buy on dips' approach.



Market Radiance : Read : Repeat

Technical

Stock of the day	Recom.	СМР (₹)	Range*	SL	Target
SBIN	BUY	807.75	806-808	785	850



(0)	Name	Price	Price %
Stocks o	VIPIND	370.00	9.537
n St ap	KEC	796.00	7.95 7
Momentum Midcap	ANURAS	963.00	7.157
ame	EASEMYTRIP	11.81	لا 3.28
ž	GODREJIND	1124.70	4.08

796.00	7.957
963.00	7.157
11.81	ע3.28
1124.70	لا4.08

+	PSU banking stocks are gaining traction,
	with SBIN witnessing a catch-up move.

- The stock recently broke out of an inverted head and shoulders pattern, though the breakout was short-lived leading to a pullback in line with market trend.
- However, it has since resumed its upward + trend, forming a pivot above the breakout zone, which aligns with the moving average ribbon.
- We anticipate a sustained up move hereon, potentially materializing the pattern breakout.

Name	Price	Price %	-
HFCL	90.20	5.317	Rang Br
DEEPAKNTR	2064.00	4.247	e e
TRENT	5573.00	3.947	Break
ALKEM	5319.00	3.74 7	vn (out
MUTHOOTFIN	2108.00	6.72	-

Name	Price	Price %	Тор
MUTHOOTFIN	2108.00	6.72×	т б
TIINDIA	2912.00	4.18	F&O
CESC	162.80	2.99 ۷	
BSE	7150.00	2.68	Losers
UNIONBANK	132.05	لا 2.13	Ľ

Name	Price	Price %	
CHAMBLFERT	636.50	וב 1.77	Bearish
CROMPTON	327.35	الا1.22	
JUBLFOOD	684.90	لا 1.28	Charts
MUTHOOTFIN	2108.00	6.72	rts
TIINDIA	2912.00	4.18	

Bullish Charts

Name	Price	Price %
HEROMOTOCO	4318.00	6.177
HFCL	90.20	5.317
JSWSTEEL	1037.00	4.827
TATAMOTORS	729.00	4.307
DEEPAKNTR	2064.00	4.247

Name	Price	Price %
GRASIM	2829.50	3.377
HEROMOTOCO	4318.00	6.177
IRB	51.10	3.617
LODHA	1370.00	4.067
NAUKRI	1506.00	3.587
LODHA	1370.00	4.06



Market Radiance Click : Read : Repeat

Research Team

Name	Email ID
Ajit Mishra	ajit.mishra@religare.com
Abhijeet Banerjee	abhijeet.banerjee@religare.com
Gaurav Sharma	gauravsharma2@religare.com
Ashwani Harit	ashwani.harit@religare.com
Divya Parmar	divya.parmar@religare.com
Vinay Kalani	vinay.kalani1@religare.com
Rajan Gupta	rajan.gupta1@religare.com



Disclaimer

Before you use this research report, please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: https://www.religareonline.com/disclaimer

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/ are as under:

Statements on ownership and material conflicts of interest, compensation- Research Analyst (RA) [Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) below, are given separately]:

S. No.	Statement	Answer	
		Yes	No
	I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of Interest is given below this table]		No
	I/we or any of my/our relatives, have actual/beneficial ownership of one percent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No
	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?		No
	I/we have received any compensation from the subject company in the past twelve months?		No
	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No
	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No
	I/we have served as an officer, director or employee of the subject company?		No
	I/we have been engaged in market making activity for the subject company?		No

Market Radiance

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) above, are given below]

SS. No.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results